Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Pamela Acha"'
Autor:
Guillermo Serrano, Nerea Berastegui, Aintzane Díaz-Mazkiaran, Paula García-Olloqui, Carmen Rodriguez-Res, Sofia Huerga-Dominguez, Marina Ainciburu, Amaia Vilas-Zornoza, Patxi San Martin-Uriz, Paula Aguirre-Ruiz, Asier Ullate-Agote, Beñat Ariceta, Jose-Maria Lamo-Espinosa, Pamela Acha, Oriol Calvete, Tamara Jimenez, Antonieta Molero, Maria Julia Montoro, Maria Díez-Campelo, David Valcarcel, Francisco Solé, Ana Alfonso-Pierola, Idoia Ochoa, Felipe Prósper, Teresa Ezponda, Mikel Hernaez
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-17 (2024)
Abstract While myelodysplastic syndromes with del(5q) (del(5q) MDS) comprises a well-defined hematological subgroup, the molecular basis underlying its origin remains unknown. Using single cell RNA-seq (scRNA-seq) on CD34+ progenitors from del(5q) MD
Externí odkaz:
https://doaj.org/article/91536052d5734ebda987ce77dddb892b
Autor:
Ignacio Campillo-Marcos, Marta Casado-Pelaez, Veronica Davalos, Gerardo Ferrer, Caterina Mata, Elisabetta Mereu, David Valcarcel, Antonieta Molero, Lurdes Zamora, Laura Palomo, Pamela Acha, Ana Manzanares, Francesc Sole, Manel Esteller
Publikováno v:
HemaSphere, Vol 7, p e4630768 (2023)
Externí odkaz:
https://doaj.org/article/ecffb9aaeabb40ef88bcdffac1d0430f
Autor:
Oriol Calvete, Julia Mestre, Ruth M. Risueño, Ana Manzanares, Pamela Acha, Blanca Xicoy, Francesc Solé
Publikováno v:
Biomedicines, Vol 11, Iss 12, p 3222 (2023)
Next-generation sequencing (NGS) tools have importantly helped the classification of myelodysplastic syndromes (MDS), guiding the management of patients. However, new concerns are under debate regarding their implementation in routine clinical practi
Externí odkaz:
https://doaj.org/article/4636b85de0d74f138ff07e445d0865a7
Autor:
Simona Colla, Gerd A. Blobel, Guillermo Garcia-Manero, Karen Clise-Dwyer, Gheath Al-Atrash, Valeria Santini, Stephanie Halene, Jennifer S. Carew, Rafael Bejar, Tuyet M. Tan, Matteo Pellegrini, Carlos Bueso-Ramos, Yuanbin Song, Irene Gañán-Gómez, Valeria Visconte, Jaroslaw P. Maciejewski, Margherita Cassari, Pamela Lockyer, Francesc Sole, Pamela Acha, Feng Wang, Scott A. Peslak, Hui Yang, Guillermo Montalban-Bravo, Natthakan Thongon, Rashmi Kanagal-Shamanna, Feiyang Ma, Vera Adema
Supplementary Data from Targeting the EIF2AK1 Signaling Pathway Rescues Red Blood Cell Production in SF3B1-Mutant Myelodysplastic Syndromes With Ringed Sideroblasts
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5865c40b6e6adc3d75741f8245104f3f
https://doi.org/10.1158/2643-3230.22545554
https://doi.org/10.1158/2643-3230.22545554
Autor:
Simona Colla, Gerd A. Blobel, Guillermo Garcia-Manero, Karen Clise-Dwyer, Gheath Al-Atrash, Valeria Santini, Stephanie Halene, Jennifer S. Carew, Rafael Bejar, Tuyet M. Tan, Matteo Pellegrini, Carlos Bueso-Ramos, Yuanbin Song, Irene Gañán-Gómez, Valeria Visconte, Jaroslaw P. Maciejewski, Margherita Cassari, Pamela Lockyer, Francesc Sole, Pamela Acha, Feng Wang, Scott A. Peslak, Hui Yang, Guillermo Montalban-Bravo, Natthakan Thongon, Rashmi Kanagal-Shamanna, Feiyang Ma, Vera Adema
SF3B1 mutations, which occur in 20% of patients with myelodysplastic syndromes (MDS), are the hallmarks of a specific MDS subtype, MDS with ringed sideroblasts (MDS-RS), which is characterized by the accumulation of erythroid precursors in the bone m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15eefc26f69885c0b23548b2c2fd7753
https://doi.org/10.1158/2643-3230.c.6550976.v1
https://doi.org/10.1158/2643-3230.c.6550976.v1
Autor:
Albert Esquirol, Yolanda Guillén, Elena Bussaglia, Vanesa Criado, Maite Carricondo, Pamela Acha, Manel Esteller, Jorge Sierra, Francesc Solé, Anna Bigas, Josep F Nomdedeu
Publikováno v:
Blood. 140:11786-11787
Autor:
Ignacio Campillo-Marcos, Marta Casado-Pelaez, Veronica Davalos, Gerardo Ferrer, Caterina Mata, Elisabetta Mereu, David Valcarcel, Antonieta Molero, Lurdes Zamora, Laura Palomo, Pamela Acha, Ana Manzanares, Francesc Solé, Manel Esteller
Publikováno v:
Cancer Research. 83:LB130-LB130
Epigenetic alterations, such as DNA methylation aberrations, are a hallmark of human cancer. This observation has led to the assessment of hypomethylating agents (HMAs) as potential drugs to treat oncological patients, being considered the clinical a
Publikováno v:
Cancers. 14:5531
Myelodysplastic syndromes (MDS) are a group of clonal hematological neoplasms characterized by ineffective hematopoiesis in one or more bone marrow cell lineages. Consequently, patients present with variable degrees of cytopenia and dysplasia. These
Autor:
Manja Meggendorfer, Lurdes Zamora, Irene Fuhrmann, Vera Adema, Francesc Solé, Cassandra M Kerr, Claudia Haferlach, Blanca Xicoy, Laura Palomo, Torsten Haferlach, Wolfgang Kern, Pamela Acha, Sven Twardziok, Jaroslaw P. Maciejewski, Stephan Hutter, Francisco Fuster-Tormo
Publikováno v:
Blood. 136(16)
More than 90% of patients with myelodysplastic/myeloproliferative neoplasms (MDSs/MPNs) harbor somatic mutations in myeloid-related genes, but still, current diagnostic criteria do not include molecular data. We performed genome-wide sequencing techn
Autor:
Marcus Hentrich, Jordi Esteve, Matteo G. Della Porta, Mar Tormo, Sigrid Machherndl-Spandl, Ana Garrido, Sonia Matos, Annika Dufour, Olga Salamero, Jorge Sierra, Marta Pratcorona, Lisa Pleyer, Federico Lussana, Maria Carmo-Fonseca, Francesco Passamonti, Paola Fazi, Albertina Nunes, Sonja Heibl, Susana Vives, Christoph Sippel, Nicola Stefano Fracchiolla, Alfonso Piciocchi, Joana M. P. Desterro, Montserrat Arnan, Pamela Acha, Erica Travaglino, Aida Botelho de Sousa, Friedrich Stölzel, Maria Teresa Voso, Giulia Maggioni, Christian Thiede, Claudia Basilico, Cristina Astrid Tentori, Francesc Solé, Karsten Spiekermann, Marcos Lemos, Klaus H. Metzeler, Elisabetta Todisco, Bernhard Heilmeier, Jan Moritz Middeke, Marina Diaz, Valentina Mancini, David Gallardo
Publikováno v:
Blood. 136:30-31
Introduction. Mutations in genes encoding the metabolic enzymes isocitrate dehydrogenase (IDH) 1 and 2 are found in 10-20% of patients with acute myeloid leukemia (AML). Recently, IDH inhibitors have shown good clinical response in patient's refracto